Biological and clinical features of STAT3-mutated and STAT3 wild-type Tγδ LGLL patients
| . | STAT3 mutated, n/N (%) . | STAT3 wild-type, n/N (%) . | P value . |
|---|---|---|---|
| Age > 65 y | 15/37 (40.5) | 11/59 (18.6) | .0324 |
| LGL > 2000/mm3 | 8/32 (25.0) | 7/46 (15.2) | .3824 |
| CD16 expression | 18/27 (66.7) | 29/40 (72.5) | .7860 |
| CD56 expression | 1/26 (3.8) | 23/41 (56.1) | <.0001 |
| CD57 expression | 21/27 (77.8) | 34/41 (82.9) | .7541 |
| KIR expression | 2/10 (20.0) | 12/24 (50.0) | .1413 |
| CD158a expression | 0/10 (0) | 3/24 (12.5) | .5388 |
| CD158b expression | 1/10 (10.0) | 8/24 (33.3) | .2250 |
| CD158e expression | 1/10 (10.0) | 3/24 (12.5) | >.9999 |
| CD94 expression | 7/18 (38.9) | 20/35 (57.1) | .2542 |
| NKG2A expression | 1/10 (10.0) | 10/24 (41.7) | .1133 |
| NKG2C expression | 1/8 (12.5) | 2/22 (9.1) | >.9999 |
| Vδ1+ | 7/12 (58.3) | 9/24 (37.5) | .2983 |
| Vδ2+ | 0/17 (0) | 17/34 (50.0) | .0003 |
| Vγ9+ | 4/16 (25.0) | 20/35 (57.1) | .0400 |
| ANC < 1500/mm3 | 23/35 (65.7) | 20/49 (40.8) | .0288 |
| ANC < 500/mm3 | 11/35 (31.4) | 6/49 (12.2) | .0519 |
| Hb < 120 g/L | 19/34 (55.9) | 17/49 (34.7) | .0726 |
| Hb < 90 g/L | 10/34 (29.4) | 6/49 (12.2) | .0874 |
| PLTs < 100 000/mm3 | 6/34 (17.6) | 7/49 (14.3) | .7628 |
| Splenomegaly | 8/35 (22.9) | 11/53 (20.8) | >.9999 |
| Autoimmune/inflammatory diseases | 19/32 (59.4) | 17/54 (31.5) | .0139 |
| SPMs | 6/28 (21.4) | 10/44 (22.7) | >.9999 |
| Need for treatment | 19/28 (67.9) | 18/48 (37.5) | .0169 |
| . | STAT3 mutated, n/N (%) . | STAT3 wild-type, n/N (%) . | P value . |
|---|---|---|---|
| Age > 65 y | 15/37 (40.5) | 11/59 (18.6) | .0324 |
| LGL > 2000/mm3 | 8/32 (25.0) | 7/46 (15.2) | .3824 |
| CD16 expression | 18/27 (66.7) | 29/40 (72.5) | .7860 |
| CD56 expression | 1/26 (3.8) | 23/41 (56.1) | <.0001 |
| CD57 expression | 21/27 (77.8) | 34/41 (82.9) | .7541 |
| KIR expression | 2/10 (20.0) | 12/24 (50.0) | .1413 |
| CD158a expression | 0/10 (0) | 3/24 (12.5) | .5388 |
| CD158b expression | 1/10 (10.0) | 8/24 (33.3) | .2250 |
| CD158e expression | 1/10 (10.0) | 3/24 (12.5) | >.9999 |
| CD94 expression | 7/18 (38.9) | 20/35 (57.1) | .2542 |
| NKG2A expression | 1/10 (10.0) | 10/24 (41.7) | .1133 |
| NKG2C expression | 1/8 (12.5) | 2/22 (9.1) | >.9999 |
| Vδ1+ | 7/12 (58.3) | 9/24 (37.5) | .2983 |
| Vδ2+ | 0/17 (0) | 17/34 (50.0) | .0003 |
| Vγ9+ | 4/16 (25.0) | 20/35 (57.1) | .0400 |
| ANC < 1500/mm3 | 23/35 (65.7) | 20/49 (40.8) | .0288 |
| ANC < 500/mm3 | 11/35 (31.4) | 6/49 (12.2) | .0519 |
| Hb < 120 g/L | 19/34 (55.9) | 17/49 (34.7) | .0726 |
| Hb < 90 g/L | 10/34 (29.4) | 6/49 (12.2) | .0874 |
| PLTs < 100 000/mm3 | 6/34 (17.6) | 7/49 (14.3) | .7628 |
| Splenomegaly | 8/35 (22.9) | 11/53 (20.8) | >.9999 |
| Autoimmune/inflammatory diseases | 19/32 (59.4) | 17/54 (31.5) | .0139 |
| SPMs | 6/28 (21.4) | 10/44 (22.7) | >.9999 |
| Need for treatment | 19/28 (67.9) | 18/48 (37.5) | .0169 |
P values are calculated using Fisher exact test. Significant P values are reported in bold.